MGM-15

MGM-15 (dihydro-7-hydroxymitragynine), the long-acting reduced 7-OH. The same compound sold under the labels MIT-A and (mislabeled) DHM. Chemistry, the COA-testing problem, regulatory landscape, taper plan, Suboxone induction notes.

What it is

MGM-15 is a semi-synthetic opioid made by chemically reducing 7-OH. It is the 1,2-dihydro version of 7-OH. Academic papers also call it “Dihydro-7-Hydroxy Mitragynine” or “DH7OH MG”; forensic-chemistry monographs use “Dihydro-7-Hydroxy Mitragynine.”

Products sold in U.S. consumer markets as “DHM” or “MIT-A” are the same compound, often blended with concentrated mitragynine in ratios that vary by vendor and batch. The “DHM” label borrows from the technical name (dihydro-7-hydroxymitragynine) while obscuring that the named compound is reduced from 7-OH, not from mitragynine. “MIT-A” is marketed as “Mitragynine plus Advanced Alkaloids” or close variants — wellness-style branding that doesn’t disclose what’s actually in the product. Across community testing references, forensic detections, and label-vs-effect disputes, both labels converge on the same picture: MGM-15 plus concentrated mitragynine.

Where it came from

Japanese researchers first reported MGM-15 in Matsumoto et al. 2014 as a candidate analgesic. It sat in the academic literature for about a decade before showing up in U.S. designer-drug products in early 2025. Its fluorinated analog, MGM-16 (10-fluoro per natural-product numbering, 9-fluoro per IUPAC; the same atom in two conventions), is 240× the potency of morphine in a mouse tail-flick antinociception assay per Matsumoto 2014. MGM-16 has not shown up in U.S. consumer products; MGM-15 has.

How MGM-15 is made (and why “reducing mitragynine” wouldn’t work)

7-OH (7-hydroxymitragynine) carries an isolated imine bond (C=N) at the C2 position of its indolenine ring system. Sodium borohydride (NaBH₄) is a mild hydride donor that reduces imines to amines under gentle conditions in methanol at low temperature. The reaction is highly selective: NaBH₄ does not touch the β-methoxyacrylate ester, doesn’t disturb the rest of the molecule, and produces one dominant diastereomer. The product is MGM-15.

Reducing mitragynine instead of 7-OH doesn’t give a clean product. Mitragynine has no isolated imine for NaBH₄ to grab; its C2-C3 bond is part of an aromatic indole. Reducing a bond in an aromatic ring requires breaking pyrrole aromaticity, which NaBH₄ in methanol won’t do. Forcing the reduction with stronger reagents collapses selectivity: the β-methoxyacrylate ester becomes a target, multiple stereocenters form, and the result is a mixture of partially-, fully-, and over-reduced compounds rather than one defined molecule. And the product of reducing mitragynine’s indole has no 7-hydroxyl, no meaningful mu-opioid receptor activity, and no commercial reason to make it.

The actual synthesis route documented in the analytical-chemistry record:

  • Not: mitragynine → reduction → new compound called “DHM.”
  • Actually: mitragynine → chemical oxidation to 7-OH (the same upstream route the FDA documents for the concentrated 7-OH wave) → NaBH₄ reduction to MGM-15 → blending with concentrated mitragynine → sale under the MIT-A or DHM label.

One reduction pathway, one defined potent compound, blended with a varying amount of mitragynine to produce a marketable effect profile and read on standard analytical testing as “mostly mitragynine.”

Pharmacology

A high-affinity partial agonist at the mu-opioid receptor (Kᵢ ~6.4 nM) and at the delta-opioid receptor (Kᵢ ~16 nM) (Matsumoto et al. 2014; confirmed in Gour et al., Drug Test Anal 2025, which characterizes MGM-15 as showing greater hMOR and hDOR binding affinities than 7-OH). The dual MOR/DOR action matters: medications that only hit mu, like buprenorphine, leave the delta side uncovered.

In mouse antinociception assays MGM-15 is roughly 15× more potent than morphine subcutaneously and 50× orally (Matsumoto 2014). The 240×-morphine figure that circulates in community discussion belongs to MGM-16, not MGM-15.

Duration

No published human pharmacokinetic data for MGM-15 exists as of mid-2026. Earlier versions of this page cited a 15-hour half-life with no traceable primary source; the figure has been removed. Community-reported effective duration clusters at 9–15 hours per dose, against 7-OH’s 2–4 hours. Treat the duration claim as anecdotal until human PK is published.

Practical consequences of the longer duration the community reports:

  • Withdrawal onset is delayed compared to 7-OH. Users describe waiting 24 to 48+ hours after the last dose for symptoms to climb.
  • Dose-stacking without realizing it happens easily. Redosing on a 7-OH schedule puts MGM-15 well into accumulation.

Effect profile (versus pure 7-OH)

Recurring patterns from community reports across multiple subreddits and the Discord:

  • Less euphoria, more pain relief. A frequent characterization: “MGM is great for pain relief but euphoria doesn’t come close to 7-OH.”
  • Longer duration. 9–15 hours per dose versus 7-OH’s 2–4.
  • More sedating, more nodding. Users describe being “knocked out” at doses 7-OH wouldn’t produce.
  • GI distress on first exposure is a common report among users transitioning from 7-OH.

Dose patterns in U.S. consumer products

Per-tablet or per-shot mitragynine-content equivalents on these products cluster at 5–30 mg per dose, with daily totals ranging from ~10 mg/day low-end to 100+ mg/day at the heavy end. The most-cited rough equivalence: 10 mg of MGM-15 produces effects comparable to 30–40 mg of 7-OH, around a 3–4× potency factor. One specific product reported repeatedly is “MIT-A” tablets at 28 mg each, taken three to four times daily.

Inter-product and within-brand batch variability is the norm, not the exception. “Each brand’s composition is different” recurs across direct comparison threads. Users describe a single brand’s tablets visually changing between batches (different filler appearance) and producing different effects. These patterns are what would be expected if MGM-15 content varies between batches and vendors without a standardized formulation.

Standard testing misses MGM-15

When MGM-15 is analyzed by gas chromatography–mass spectrometry (GC-MS), the high-temperature inlet drives the reduction backwards. The dihydro derivative loses hydrogen and reverts to mitragynine before the molecule reaches the detector. The CFSRE forensic-chemistry monograph calls this out directly: “Analysis of dihydro-7-hydroxy mitragynine is challenging due to the analytical conversion of dihydro-7-hydroxy mitragynine to mitragynine during GC-MS analysis.” The monograph’s recommended methods: LC-QTOF-MS or LC-MS/MS.

The consequence for COAs. A vendor running GC-MS testing on a MIT-A or DHM product gets a report showing high mitragynine and low or non-detect 7-OH. That report is technically accurate within the method. The MGM-15 — the active opioid-receptor-active compound producing the product’s effects — is invisible.

LC-MS/MS (liquid chromatography–tandem mass spectrometry) and LC-QTOF-MS keep the inlet near ambient temperature. MGM-15 survives the analytical run and shows up as itself. For products marketed as MIT-A or DHM, those are the methods that can actually verify what’s in them. Vendors that publish only GC-MS COAs are not providing meaningful verification of the active compound.

The community has independently identified this reversion pattern without using the GC-MS vocabulary. Recurring rebuttals to vendor “the COA shows only MIT” claims: “there’s no MIT tablet that produces the effects these things do.”

The regulatory landscape

Restrictions on standalone 7-OH at the U.S. state level in 2025 drove the market shift these products fill. As of mid-2026:

  • Florida. Fla. Admin. Code 2ER25-2 (effective Aug 19, 2025; re-issued Dec 8, 2025) added 7-hydroxymitragynine concentrated above 400 ppm (0.04%) on a dry-weight basis to Schedule I. The rule names 7-OH specifically; MGM-15 falls outside the threshold language as written. Pending 2026 session bills (SB 994 / HB 1205) would make the threshold permanent statute. Press coverage citing “1%” is inaccurate.
  • Louisiana. Act 41 / SB 154 (effective Aug 1, 2025) places both mitragynine and 7-OH on Schedule I under R.S. 40:964(G), with “salts, isomers, or salts of isomers” language that likely captures MGM-15.
  • Ohio. OAC 4729:9-1-01.1 (effective Dec 12, 2025 per Gov. DeWine announcement) explicitly names “7-hydroxymitragynine; Mitragynine pseudoindoxyl; Dihydro-7-hydroxy mitragynine; and 7-acetoxymitragynine.” Ohio is the only state rule located that names MGM-15 by chemical name.
  • Tennessee, Mississippi, South Carolina, and other states have variously restricted 7-OH. MIT-A and DHM market presence concentrates in these jurisdictions.
  • Older kratom-ban states (AL, AR, IN, RI, VT, WI) have broad bans that presumptively capture MGM-15 as a kratom-derived compound.
  • Federal. On July 1, 2026, DEA filed a notice of intent to temporarily place MGM-15, mitragynine pseudoindoxyl, and MGM-16 in Schedule I (Docket DEA-1644). The earliest the order can take effect is August 5, 2026. See The Federal 7-OH Ban for dates and process.

The regulatory-niche pattern. The geographic concentration of MIT-A and DHM products in Florida specifically, where the rule names 7-OH only and the 400 ppm threshold creates space for a product that reads as “mitragynine plus trace 7-OH” on GC-MS, is the clearest example of a regulatory gap filling. Ohio’s December 2025 rule, naming dihydro-7-hydroxy mitragynine by name, started closing it. The pattern is observable; producer intent is consistent with the evidence without being directly proven.

Withdrawal severity

Two patterns recur in community reports:

  • MGM-15-containing products substitute for 7-OH withdrawal in most reports. Users transitioning from 7-OH to MIT-A or DHM products describe the new product handling the acute physical symptoms.
  • Coming off these products is harder than coming off 7-OH. Short-term users describe withdrawal as more severe than what they remembered from 7-OH at comparable use durations. The community attributes this to MGM-15’s longer duration (longer washout) and its delta-opioid receptor activity (which buprenorphine antagonizes). The delta-receptor claim is consistent with the published MGM-15 binding profile; the practical effect is widely reported.

Suboxone is tricky with MGM-15

1. Your withdrawal score just takes longer to climb. The site gates Suboxone induction on your SOWS or COWS score, not the clock. If you’re inducting at home, SOWS is the self-scored tool; wait until SOWS ≥ 17 (or COWS ≥ 12) regardless of how many hours it’s been. That’s what protects you from inducting before your receptors have cleared enough. MGM-15’s longer duration means hitting the threshold takes longer than with 7-OH. Plan for closer to 36 to 72 hours past the last dose, not the 14 to 24 a 7-OH wait runs.

2. Micro-induction (Bernese method) gets messier with MGM-15. Micro-induction starts tiny bupe doses while you keep taking your opioid, no withdrawal wait. With MGM-15’s high MOR affinity, even 1 to 2 mg bupe doses can displace enough MGM-15 to trigger precipitated withdrawal. Community members have reported micro-induction attempts where every time the bupe dose reached 1 to 2 mg, PWD set in and the process became intolerable.

3. Even after a clean induction, bupe may not cover all the symptoms.

  • Buprenorphine has a ceiling effect. Its maximum MOR activation sits below what MGM-15 was delivering. You’re stepping down on opioid signaling.
  • MGM-15 activates both mu and delta receptors. Buprenorphine hits mu and antagonizes delta. The delta-side contribution to mood, analgesia, and overall opioid tone goes away when you switch to bupe. 7-OH is mu-dominant, so this gap hits harder coming off MGM-15 than coming off 7-OH.
  • Net effect: people coming off MGM-15 onto Suboxone report bupe doesn’t cover them. Restlessness, low mood, anhedonia, and a low-grade “off” feeling persist. Stabilization runs 2 to 3 weeks. Community members coming off MGM-15 have needed higher stabilizing doses than their induction dose to settle. See Depression and Anhedonia for the mood and anhedonia treatment picture.

Community knowledge on MGM-15 is ahead of the published literature. Share what’s worked or hasn’t.

SR-17 as the other community-validated path

SR-17 is the second MAT-equivalent option the community has converged on for getting off the synthetics, and it applies to MGM-15. SR-17 is a biased mu agonist with a long duration of action, which sidesteps the Suboxone-affinity problem above. There’s no partial-agonist displacement to trigger precipitated withdrawal. The SR-17 page covers the protocol and dose ranges community members have used for long-acting compounds like MGM-15. It also documents the unknowns. SR-17 is off-prescription and unregulated; the Suboxone path carries the clinical safety net. Both are legitimate paths; pick based on your situation.

For the reader being sold one of these products

The working picture: low-dose MGM-15 plus concentrated mitragynine, with composition varying by vendor and batch and not standardized.

  • These products contain opioid-receptor-active compounds. User-reported effects confirm this.
  • A GC-MS COA showing “mitragynine, no 7-OH” on a product producing opioid-class effects is the analytical method hiding the active compound, not the product being mild.
  • For meaningful verification, look for LC-MS/MS or LC-QTOF-MS analysis. Be prepared for those tests to show MGM-15 even when GC-MS doesn’t.
  • Dependence on these products produces opioid withdrawal. The withdrawal arc is longer than 7-OH withdrawal because MGM-15’s duration is longer. Standard Suboxone induction often needs a longer washout (36–72 hours) and may not cover the first 2–3 days well; community reports consistently describe this. See Suboxone, SR-17, the COWS & SOWS induction guide, and Why Suboxone Might Not Be Working.
  • For the live discussion of what specific products are being sold and what the latest testing shows, the Discord and r/quitting7oh are the places to go.

Open questions and limits

This page documents what’s established and what’s reasonably inferred. What isn’t:

  • Exact composition of any specific product is not publicly characterized. MGM-15 to mitragynine ratio varies by vendor and batch. Other compounds may be present.
  • Human pharmacokinetic data for MGM-15 specifically have not been published. The 9–15 hour duration figure is anecdotal community observation, not measured PK.
  • Long-term safety profile is unknown. MGM-15 has been characterized in vitro and in mouse antinociception; chronic-dose dependence trajectory and side-effect profile in humans are not in the published literature.
  • The dependence pattern depends on the actual composition. Products with higher MGM-15 content produce dependence closer to 7-OH; products that lean heavier on mitragynine sit somewhere between leaf dependence and 7-OH dependence.
  • Other compounds may be present. Pseudoindoxyl, 7-acetoxymitragynine, and other 7-OH-derived modifications have been reported in some product seizures and toxicology cases.

General risks

  • Tolerance and dependence develop fast.
  • Withdrawal resembles classical opioid withdrawal. It runs more intense and longer than 7-OH withdrawal because of the longer duration and the dual mu/delta receptor profile.
  • Respiratory depression risk rises when mixed with benzos, alcohol, gabapentinoids, or other opioids.
  • Naloxone (Narcan) reverses overdose.
  • Products sold as “MGM-15” (or as MIT-A or DHM) may contain unlabeled 7-OH, additional mitragynine derivatives, or other compounds.

Sources

Chemistry and forensic chemistry:

Regulatory:

Community sourcing: aggregated from substantive threads (≥10 comments, on-topic content) across r/quitting7oh, r/Kratom_7OH, r/Quittingfeelfree, r/quittingkratom, r/Life_After_7oh, r/7ohbuddies, r/recoverywithoutAA, r/PureLeafKratom, and r/SR17018Talk, 2025–2026.

Last updated: View source on GitHub